Latest news
Archive
- April 2024
- March 2024
- January 2024
- December 2023
- November 2023
- August 2023
- July 2023
- June 2023
- May 2023
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- April 2021
- November 2020
- October 2020
- September 2020
- July 2020
- May 2020
- December 2019
- March 2019
- February 2019
- January 2019
- December 2018
- September 2018
- July 2018
- October 2016
- May 2016
- February 2015
Advancing Equitable COVID-19 Vaccination in Humanitarian Crisis
The World Health Organization (WHO), taking the lead in responding to this pressing issue, selected hera to conduct a study on the complexities of COVID-19 vaccine deployment and administration in humanitarian settings, with a specific focus on populations of concern (PoC). The study was initiated in March 2022 and concluded in March 2023, and encompassed case studies in multiple countries deeply affected by humanitarian crises: Cox's Bazar (Bangladesh), Colombia, the Democratic Republic of the Congo (DRC), Iraq, South Sudan, and Syria.
Local production of therapeutic and supplementary food in Zambia
Market assessment of local production of ready to use therapeutic food (RUTF) and ready to use supplementary food (RUSF)
Gavi, the Vaccine Alliance’s (Gavi’s) Fragility, Emergencies and Refugees (FER) policy
Gavi, the Vaccine Alliance’s (Gavi’s) Fragility, Emergencies and Refugees (FER) policy has been in effect since June 2017.
hera to support Health Systems Global in developing a new 5-year strategic plan
A hera team, led by CEO Leen Jille and Associate Partner Giorgia Lattanzi, has been selected to support Health Systems Global (HSG) in developing its next 5-Year Strategic plan covering 2021-2026. The aim is to develop a strategic framework that continues to position HSG at “the forefront of health systems policy and research within the changing landscape of global health.”
External Evaluation of the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP) 2013-2017
hera was selected to conduct the fourth external evaluation of the HRP covering the period from January 2013 to December 2017.
Mid-term review of the EU/ACP/WHO Renewed Partnership for strengthening pharmaceutical systems and improving access to quality medicines in 15 African ACP Countries
The “The Renewed EU/ACP/WHO Partnership” (RP) was a four year programme (October 2012 – September 2016) with the overall objective to contribute to the achievement of health-related MDGs and to universal health coverage in African ACP countries by improving the availability, affordability and use of safe, effective and quality assured essential medicines for the treatment of priority acute and non-communicable diseases.
Technical support to the 3MDG Fund multi-donor program from 2012 to 2016
From 2012 to 2016, hera provided technical support to the 3MDG Fund multi-donor program in Myanmar, delivering insights through a detailed cost-effectiveness analysis of two key components of the 3MDG program.
Assessing the Impact: BMGF & DFID's Reproductive Health Programmes in Low- and Middle-Income Countries
In an effort to promote reproductive health and accessibility to quality-assured reproductive health commodities in low- and middle-income countries, the Bill & Melinda Gates Foundation (BMGF) and the Department for International Development (DFID), now known as the Foreign, Commonwealth & Development Office (FCDO), rolled out two independent, yet complementary, programmes geared towards ensuring hormonal contraceptives become more readily available, of high quality and affordable.